TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24349363
Drug: Capecitabine-based chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine-based chemotherapy
Study: 18349204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcitonin (200 IE) and ketamine (0.4 mg/kg)
Study: 18349204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcitonin and ketamine
Study: 17066247
Drug: MARB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARB regimen (metronidazole 250 mg tid + amoxicillin 500 mg qid + ranitidine 300 mg hs + bismuth 300 mg qid) for 14 days
Study: 17066247
Drug: OCA regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA regimen (omeprazole 40 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid) for 14 days
Study: 30681185
Drug: Teprenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone (150 mg/day)
Study: 15068414
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist (nizatidine, 300 mg/day)
Study: 11302295
Drug: Psychosocial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial therapy (11 individual sessions including physiologic relaxation, cognitive behavioral therapy, and cardiovascular health education)
Study: 11302295
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no psychosocial therapy)
Study: 8507888
Drug: recombinant alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant alpha‐2a interferon at doses of 3MU intramuscularly thrice weekly for 6 months
Study: 18250970
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBCT) - 15 daily visits, 2-3 minutes each at temperatures from -160°C to -110°C
Study: 8886215
Drug: Naprelan 500
Normalized name: Naprelan 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprelan 500 mg once daily
Study: 8886215
Drug: Naprelan 1000
Normalized name: Naprelan
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naprelan 1000 mg once daily
Study: 8886215
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg QID
Study: 1793782
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral mesalazine four times daily (18 patients)
Study: 1793782
Drug: Steroid enemas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid enemas twice daily (19 patients)
Study: 30615259
Drug: Quadruple low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple low CNI regimen (everolimus target trough level 3-5 ng/mL, reduced CNI with tacrolimus 3-5 ng/mL or cyclosporine 25-75 ng/mL, cell cycle inhibitor, prednisone)
Study: 30615259
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple CNI regimen (tacrolimus target trough level >5 ng/mL or cyclosporine >100 ng/mL, cell cycle inhibitor, prednisone)
Study: 25099464
Drug: Soy dietary
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy dietary supplement (isoflavone 90mg)
Study: 25099464
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone therapy (estradiol 1 mg plus noretisterone 0.5 mg)
Study: 22285123
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion (500 mL of dextrose in water (DW) 10% + 40 U of regular insulin + 40 mEq of KCl, and 2 g of MgSO(4)) at a rate of 1 mL/kg/h for 10 hours preoperatively and until the removal of the aortic cross‐clamp
Study: 22285123
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (half saline solution as placebo with an equivalent infusion rate)
Study: 7786704
Drug: Intraoperative intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative intra-arterial fibrinolytic therapy (IIFT) with 250,000 IU of urokinase over 30 minutes
Study: 2392793
Drug: Pressurised metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurised metered dose inhaler (400 micrograms salbutamol)
Study: 507163
Drug: 4% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% pilocarpine hydrochloride gel applied at bedtime
Study: 507163
Drug: 4% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% pilocarpine hydrochloride drops instilled four times daily
Study: 19403473
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment treatment and sodium hypochlorite (bleach) baths
Study: 19403473
Drug: Intranasal petrolatum
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal petrolatum ointment treatment and plain water baths (placebo)
Study: 17502459
Drug: Nanoparticular CoQ(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoparticular CoQ(10) (100 mg 3 times a day) for 3 months
Study: 17181889
Drug: NaFeEDTA capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA capsule containing 60 mg Fe once per week for IDs and IDE groups, three times per week for IDA group for nine consecutive weeks
Study: 17181889
Drug: NaFeEDTA capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA capsule containing 60 mg Fe
Study: 11890101
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,200 mg daily for 11 months)
Study: 11890101
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea (DGT) (5 mg daily for 12 months)
Study: 1973969
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy - continuous oestradiol 17‐beta 0.05 mg daily, with norethisterone acetate 0.25 mg daily for 14 of each 28 days
Study: 1973969
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy - continuous conjugated equine oestrogens 0.625 mg daily, with dl‐norgestrel 0.15 mg daily for 12 of each 28 days
Study: 1014769
Drug: Hyoscine‐N‐butyl‐bromide (HBB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butyl‐bromide (HBB) sugar‐coated tablets (5 X 20 mg/daily)
Study: 25479022
Drug: Perindopril 3.5 mg/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 3.5 mg/amlodipine 2.5 mg
Study: 25479022
Drug: Perindopril 3.5
Normalized name: AMLODIPINE 2.5MG/PERINDOPRIL 3.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 3.5 mg
Study: 21456305
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplement (200 mg ferrous sulfate) for two months
Study: 15867047
Drug: Morphine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusions
Study: 15867047
Drug: Morphine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine doses before intubation and at 25 to 72 hours
Study: 10326317
Drug: Rocking bed
Normalized name: edible rock crab preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocking bed therapy
Study: 7549814
Drug: Lowering fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering fat consumption to 20% of daily calories
Study: 1790545
Drug: Trimethoprim and
Normalized name: Trimethoprim and derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim and rifampin (TMP/R) 20 mg/kg/day
Study: 1790545
Drug: Ampicillin (AMP)
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin (AMP) 150 mg/kg/day
Study: 31287890
Drug: Pre-hatch egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hatch egg weight (increased from 47.0 to 54.0 g)
Study: 28412230
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus a multi-modal oral health promotion program (Oral Health 4 Life) integrated within the quitline services
Study: 21708838
Drug: 0.40 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.40 g/kg of alcohol
Study: 21708838
Drug: 0.13 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.13 g/kg of alcohol
Study: 19246474
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of reboxetine (selective NE reuptake inhibitor)
Study: 19699148
Drug: therapeutic CPAP
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapeutic CPAP (tCPAP) after one treatment night
Study: 11563806
Drug: High-Intensity (HI)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity (HI) group: NRT, 4 advice and education sessions, and 12 weeks of individualized cognitive-behavioral therapy
Study: 7869999
Drug: Psyllium seeds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium seeds (3 times 3.25 g daily)
Study: 7869999
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (3 times 7 g daily)
Study: 2971403
Drug: Clodronate (Cl2MDP)
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (Cl2MDP) 1.6 g/day
Study: 24075051
Drug: ASC-enriched fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC-enriched fat grafts (20×10^6 cells per mL fat)
Study: 21411557
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg s.c. every 6 months)
Study: 19146606
Drug: Topical antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antioxidant mixture containing vitamin C, ferulic acid, and phloretin
Study: 14636464
Drug: Adenosine (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (3, 6, and 12 mg intravenous bolus doses)
Study: 14636464
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 mg or additional 5 mg intravenously)
Study: 8854770
Drug: High-dose intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intraarterial chemotherapy with percutaneous hepatic venous isolation and charcoal hemoperfusion (HVI.CHP)
Study: 8854770
Drug: Conventional intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intraarterial chemotherapy (group S)
Study: 1615378
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine 0.03 mg/kg/h
Study: 1615378
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine 0.08 mg/kg/h
Study: 1615378
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine 0.11 mg/kg/h
Study: 1615378
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine 0.15 mg/kg/h
Study: 1615378
Drug: Oral nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicardipine 90‐120 mg
Study: 6380436
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (1 ml extracted from the blood of normal individuals, administered starting 1 month postoperatively and at 3-month intervals)
Study: 6380436
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no transfer factor treatment)
Study: 27642077
Drug: NK1R antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK1R antagonist (GR205171, 5mg)
Study: 24290749
Drug: Percutaneous hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous hepatic perfusion (PHP) with venovenous bypass circuit and hemofiltration, receiving hepatic intra-arterial melphalan, 3 mg/kg for 30 minutes with 60 minutes of hemofiltration
Study: 15060495
Drug: Simulated pulpal
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated pulpal pressure with Superbond C&B adhesive luting agent
Study: 15060495
Drug: No simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: No simulated pulpal pressure with Superbond C&B adhesive luting agent
Study: 11521696
Drug: Short-term topical
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term topical prednisolone acetate 1% (0-6 months)
Study: 11521696
Drug: Long-term topical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term topical prednisolone acetate 1% (0-12 months)
Study: 30341095
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 μg) and vitamin B12 (500 μg) supplementation
Study: 25168768
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of tetanus-diphtheria vaccine
Study: 25168768
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of tetanus-diphtheria vaccine
Study: 17468196
Drug: Testosterone (sustanon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (sustanon 200 mg)
Study: 10511068
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg) three times a day with meals for 1 year
Study: 7589043
Drug: 200 mg.day-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg.day-1 bezafibrate
Study: 7589043
Drug: 400 mg.day-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg.day-1 bezafibrate
Study: 7589043
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (probucol + bezafibrate)
Study: 84263
Drug: Chlorpromazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (1 mg/kg intramuscularly or 1 mg/kg orally)
Study: 28303842
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide (100 mg, three times a day) one day before examination combined with scopolamine butylbromide (20 mg) 10 min before colonoscopy (Group A)
Study: 28303842
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide alone on the day of colonoscopy (100 mg, three times a day) (Group B0)
Study: 28303842
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide alone one day before colonoscopy (100 mg, three times a day) (Group B1)
Study: 28303842
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide alone two days before colonoscopy (100 mg, three times a day) (Group B2)
Study: 28303842
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide alone (20 mg) before colonoscopy (Group C)
Study: 25726210
Drug: Chia flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chia flour (35 g/day)
Study: 15310350
Drug: Oral celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral celecoxib 200 mg
Study: 12406587
Drug: 11 g
Normalized name: PSMA-11 Ga 68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 g elderberry concentrate (containing 1.9 g of anthocyanins) diluted with water
Study: 12406587
Drug: 11 g
Normalized name: PSMA-11 Ga 68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 g elderberry concentrate (containing 1.9 g of anthocyanins) diluted with 30 g sucrose
Study: 9832096
Drug: Low-dose isoproterenol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isoproterenol (3- and 5-microg/min)
Study: 9832096
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (after drug-free state)
Study: 9832096
Drug: High-dose isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isoproterenol infusion and nitroglycerin
Study: 7661125
Drug: Low meat
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low meat with mineral supplements diet (LS)
Study: 2788004
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated sodium salicylate 4.8 g daily
Study: 2788004
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 4.8 g daily
Study: 388397
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (250 mg, increased to 500 mg if warranted)
Study: 388397
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg, increased to 100 mg if warranted)
Study: 28915304
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in 2010
Study: 28915304
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in 2008
Study: 28915304
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine initiation in 2009
Study: 28915304
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine completion in 2010
Study: 28915304
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine completion in 2008
Study: 28915304
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine completion in 2009
Study: 23379490
Drug: Intravenous alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfacalcidol once weekly
Study: 15458450
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg and 80 mg daily)
Study: 10657833
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide therapy (IVCY) for 36 months
Study: 8841155
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg taken simultaneously with triazolam
Study: 8841155
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg taken 3 hours before triazolam
Study: 8841155
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg taken 12 hours before triazolam
Study: 8841155
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg taken 24 hours before triazolam
Study: 31434161
Drug: Barcode-assisted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barcode-assisted medication administration (BCMA) system
Study: 29798256
Drug: Cetylpyridinium Chloride
Normalized name: Cetylpyridinium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetylpyridinium Chloride Buccal Tablets
Study: 23886754
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GH treatment initially)
Study: 21276660
Drug: Early excision
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early excision and grafting (E&G)
Study: 16412989
Drug: Vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin therapy (oral folic acid, B‐12, and pyridoxine) for 3 months
Study: 12633007
Drug: Mailing guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailing guidelines targeted to a patient starting treatment
Study: 10695290
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (administered once or twice depending on prior vaccination status)
Study: 31178259
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (oral tablets), administered 12 and 2 hours preoperatively, and on the 2nd, 3rd, 4th, and 5th postoperative days
Study: 31178259
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (oral tablets)
Study: 25862770
Drug: Ultrasonophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonophoresis with standard treatment (supervised exercises and cryotherapy)
Study: 25862770
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with standard treatment (supervised exercises and cryotherapy)
Study: 25862770
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (supervised exercises and cryotherapy) with placebo iontophoresis and placebo ultrasonophoresis
Study: 22207250
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (experimental group listening to recorded music)
Study: 20206790
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg BID with food for 7 days and a morning dose on day 8